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mTORC1 Inhibitors in Primary Aldosteronism 
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Context.  mTORC1 activity is often increased in the adrenal cortex of patients with primary 
aldosteronism and mTORC1 inhibition decreases aldosterone production in adrenocortical 
cells, suggesting the mTORC1 pathway as a possible target for treatment of primary 
aldosteronism. 
Objective. To investigate the effect of mTORC1 inhibition on adrenal steroid hormones and 
hemodynamic parameters in mice and in patients with primary aldosteronism. 
Design. (i) Plasma aldosterone, corticosterone and angiotensin II were measured in mice 
treated for 24 hours with vehicle or rapamycin. (ii) Plasma aldosterone levels after a saline 
infusion test, plasma renin, 24-hour urine steroid hormone metabolome and hemodynamic 
parameters were measured during an open-label study in 12 patients with primary 
aldosteronism before and after two-weeks of treatment with everolimus and after a two-week 
washout period.  
Main outcome measures. (i) Change in plasma aldosterone levels. (ii) Change in other steroid 
hormones, renin, angiotensin II and hemodynamic parameters. 
Results. Treatment of mice with rapamycin significantly decreased plasma aldosterone levels 
(P = 0.007). Overall, treatment of primary aldosteronism patients with everolimus 
significantly decreased blood pressure (P < 0.05) and increased renin levels (P = 0.001) but 
did not lead to a significant reduction in aldosterone levels. However, prominent reduction of 
aldosterone levels upon everolimus treatment was observed in 4 out of 12 patients. 
Conclusion. In mice, mTORC1 inhibition was associated with reduced plasma aldosterone 
levels. In patients with primary aldosteronism, mTORC1 inhibition was associated with 
improved blood pressure and renin suppression. In addition, mTORC1 inhibition appeared to 
reduce plasma aldosterone in a subset of patients.  
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Systemic mTORC1 inhibition decreases plasma aldosterone levels in mice and in a subset of patients 
with primary aldosteronism. 
INTRODUCTION 
Primary aldosteronism (PA) is characterized by inappropriately high and relatively 
autonomous aldosterone production by the adrenal cortex, which results in hypertension, 
sodium retention, suppression of renin and increased potassium excretion. It is one of the 
most frequent causes of secondary hypertension (1), affecting around 6% of the general 
hypertensive population and up to 30% of hypertensive patients in specialized referral centers 
(2). The most common causes of PA are bilateral adrenal hyperplasia and aldosterone-
producing adrenal adenoma (APA).  
Compared with age-, sex- and blood pressure-matched patients with essential 
hypertension, patients with PA have an increased risk of cardio- and cerebrovascular 
morbidity and mortality (3,4), structural and functional renal abnormalities (5,6) and 
metabolic syndrome (7). Targeted treatment can prevent or at least partially reverse the 
consequences of PA (8-10).  
Depending on the subtype of PA, patient characteristics and preference, treatment 
comprises unilateral adrenalectomy or mineralocorticoid receptor antagonists. However, not 
all patients are suitable for surgery, and mineralocorticoid receptor antagonists can be 
associated with intolerable side effects. Therefore, additional therapeutic options are of major 
interest. 
Although mutations in ion channels and ATPases have been identified in a high 
percentage of APA patients, the molecular mechanism of PA development remains poorly 
understood (11,12). Recently, it has been demonstrated that the activity of the mammalian 
target of rapamycin complex 1 (mTORC1) is commonly increased in the adrenal glands of 
patients with PA caused by both adrenal cortex hyperplasia and aldosterone-producing 
adenoma (13). Furthermore, treatment of adrenocortical cells with an mTORC1 inhibitor 
decreases their steroid hormone production (13,14) and proliferation (13-15), and increases 
their apoptosis (16). Accordingly, mTORC1 inhibition decreases adrenocortical carcinoma 
growth in a mouse xenograft model (17).  
Here, we analyze expression of mTORC1 components in APA and investigate whether a 
systemic mTORC1 inhibition affects circulating aldosterone levels, blood pressure, and renin 
suppression in mice and in patients with PA respectively.  
MATERIALS AND METHODS 
Animal experiments 
All animal experiments were approved by the Kantonales Veterinäramt of Kanton Basel-
Stadt (Basel, Switzerland). Mice were housed at 22°C in a conventional facility with a 12 h 
light/12 h dark cycle. 13-16 weeks old C57BL/6J, 129/SvJae, BALB/cJ mice (in-house 
husbandry) were injected intraperitoneally with rapamycin (LC Laboratories, 2mg/kg of body 
weight) or vehicle (5% PEG-400, 4% ethanol, and 5% Tween 80), and euthanized after 24 
hours. Animals were injected and sacrificed between 1600 h and 1630 h. Only males were 
used in this study.  
Adrenal glands were homogenized in RIPA buffer containing Complete Proteinase 
Inhibitor Cocktail and PhosSTOP phosphatase inhibitor cocktail (both from Roche). Equal 
amounts of protein were separated by SDS-PAGE, transferred onto nitrocellulose 
membranes, and probed with antibodies against S6K, S6K-pThr389 (Cell Signaling, #2780 
and #9234) and actin (Millipore, #MAB1501). 
Plasma steroid hormone levels were determined as described previously (18) and plasma 
AngII levels were determined using AngII ELISA kit (Biotrend). 
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Immunoblot and mass spectrometry analyses of APA and matched control adrenal cortex 
samples 
Quantification of mTORC1 activity and expression of mTORC1 components and proteins 
involved in mTORC1 regulation in APA and control adrenal cortex samples (Ctrl) of the 
same adrenal is based on the analysis of immunoblot and mass spectrometry data obtained in 
the course of other investigations (19).  
Clinical study design and participants 
This open-label, proof-of-concept study was conducted at the University Hospital Basel 
between June 2017 and June 2018 and included 14 patients with PA diagnosed according to 
current guidelines of the Endocrine Society (2). Additional eligibility criteria included age 
≥18 years and an office blood pressure < 160/90 mmHg. Key exclusion criteria were signs of 
current infection, ongoing immunosuppressive treatment or documented immunodeficiency, 
clinically significant kidney or liver disease, uncontrolled congestive heart failure, and 
pregnancy or breastfeeding. Sample size was based on clinical and practical considerations 
for a pilot study. Due to costs, development of a true placebo was not affordable. All 
participants provided written informed consent after the nature and possible consequences of 
the study were explained. Subject characteristics are provided in Table 1. 
The study was approved by the regional ethical committee (EKNZ 2015-400) and 
Swissmedic (2017DR2062), and was conducted in accordance with the guidelines for Good 
Clinical Practice and the Declaration of Helsinki. The trial was registered at Clinicaltrials.gov 
(NCT03174171). 
Intervention 
All participants received everolimus (Certican®; Novartis Pharma AG) 0.75mg orally twice a 
day (b.i.d.) for 14 days. This dosing regimen is commonly used in the clinic to prevent 
allograft rejection in heart and kidney transplant patients, and has a well-described safety 
profile.  
Study Assessment 
All participants attended a screening visit and 5 study visits (Figure 1). An additional visit 
was planned to gather histological and clinical data if adrenalectomy was performed after the 
last saline infusion test. The dosage of beta-blockers, central alpha-2 agonists, angiotensin-
converting enzyme inhibitors, angiotensin receptor blockers and diuretics was maintained 
unchanged for the duration of the trial. Where applicable, subjects were taken off 
mineralocorticoid receptor antagonists at least 6 weeks before the baseline measurements. 
When required, potassium was substituted orally aiming for a serum potassium level of ≥ 3.9 
mmol/l. 
Baseline measurements included standardized 7-day home blood pressure measurements 
(Model Omron M6 or Omron M400 ) performed as recommended by the European Society of 
Hypertension (20), hemodynamic measurements using the non-invasive thoracic electrical 
bioimpedance HOTMAN system (Hemo Sapiens Inc., San Ramon, California, USA), 24 hour 
urine collection for measurement of steroid hormone metabolites, baseline plasma 
aldosterone as assessed with standardized recumbent saline infusion test (2) and other 
baseline plasma steroid hormone levels as mentioned below (visit 2 and 3). The 
measurements were repeated after 14 days of everolimus treatment (visit 5) and after a two-
week washout period (visit 6). In addition, plasma everolimus levels were measured (visit 4, 
5 and 6) to ensure medication compliance.  
Plasma aldosterone, renin, cortisol, adrenocorticotropic hormone (ACTH), 
dehydroepiandrosterone-sulfate (DHEA-S), testosterone, (17)estradiol, everolimus level and 
urine creatinine were measured at the routine laboratory, Department of Clinical Chemistry, 
University Hospital Basel, Switzerland. Aldosterone was quantified using a competitive 
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chemiluminescence immunoassay (LIAISON® Aldosterone ([REF] 310450), DiaSorin Inc., 
MN 55082, USA). Renin was measured by a non-competitive chemiluminescence 
immunoassay (LIAISON® Direct Renin ([REF] 310470), DiaSorin Inc., MN 55082, USA). 
24-hour urinary steroid hormone metabolite levels [aldosterone, tetrahydroaldosterone 
(TH-Aldo), 18-hyroxycortisol, 18-hydroxycorticosterone, 11-deoxycortisol, cortisol (F), 
tetrahydrocortisol (THF), 5α-tetrahydrocortisol (α-THF), cortisone (E), tetrahydrocortisone 
(THE), 5α-tetrahydrocortisone (α-THE), β-cortol, α-cortolone, β-cortolone, corticosterone 
and 11-dehydrocorticosterone and their tetrahydro-metabolites, 11-deoxycorticosterone, 
dehydroepiandrosterone (DHEA), progesterone, 17α-hydroxyprogesterone, androsterone, 
11β-hydroxyandrosterone, androstenedione and testosterone] were determined as follows: for 
enzymatic de-glucuronidation urinary samples (0.5 ml) were pH adjusted with sodium acetate 
buffer (1 ml, 0.1 M, pH 4.3) and incubated (2 h, 55°C) with β-glucuronidase from Helix 
pomatia (80 µl, ≥ 100 000 U/ml; Sigma-Aldrich) prior solid-phase extraction (SPE). For 
extraction of free urinary steroids by SPE, de-conjungated urine samples (1.5 ml) and non-
treated urine (1 ml) samples were diluted with sodium acetate buffer (0.1 M, pH 4.3) 
containing internal standard solution (aldosterone-D7 (4 ng/ml), THF-D5 (750 ng/ml), F-D4 
(300 ng/ml), E-D2 (300 ng/ml), 11-deoxycortisol-D5 (45 ng/ml), B-D8 (75 ng/ml), 
testosterone-D2 (15 ng/ml), 17-OH-progesterone-D8 (150 ng/ml), androstenedione-D7 (45 
ng/ml), DHEA-D6 (450 ng/ml), progesterone-D8 (75 ng/ml), etiocholanolone-D5 (300 
ng/ml) and androsterone-D2 (450 ng/ml)) to a final volume of 2 ml. Samples were 
centrifuged (10 min, 16 000 x g, 4 °C) and supernatants (1.5 ml) were transferred to Oasis 
HBL SPE (60 mg, 3 cc; Waters) cartridges, preconditioned with ethyl acetate and water (3 ml 
each). Columns were washed with water/ammonium hydroxide (3 x 1 ml, 98/2, v/v), 
methanol/water/ammonium hydroxide (3 x 1 ml, 20/78/2, v/v/v) and water (3 x 1 ml). 
Steroids were eluted with ethyl acetate (2 x 0.75 ml), evaporated to dryness (1.5 h, 35°C) and 
reconstituted in methanol (50 µl, 10 min, 4°C, 1300 rpm). Steroid content was analyzed by 
ultra-performance liquid chromatography-MS/MS (UPLC-MS/MS) using an Agilent 1290 
UPLC coupled to an Agilent 6490 triple quadrupole mass spectrometer equipped with a jet-
stream electrospray ionization interface (Agilent Technologies). Analyte separation was 
achieved within 19 min using a reverse-phase column (1.7 µm, 2.1 mm x 150 mm; Acquity 
UPLC BEH C18; Waters) and water-acetonitrile-formic acid (B: 95/5/0.1; v/v/v) and (A: 
5/95/0.1; v/v/v) as mobile phases. Data acquisition and quantitative analysis was performed 
by MassHunter (Version B.09.00, Agilent Technologies). Tetrahydrocortisol, 5α-
tetrahydrocortisol, tetrahydrocortisone, α- and β-cortolone, β-cortol, 11-deoxycortisol, 
cortisol and cortisone were summarized as total glucocorticoid metabolites for analysis. 
Small volumes and low 24-hour creatinine levels of the returned urine recorded for some 
patients indicated possible incomplete 24-hour collection. To correct for this, we normalized 
metabolite concentrations to the 24-hour creatinine value. 
Study Endpoints 
The predefined primary endpoint was change in plasma aldosterone in the standard 
recumbent saline infusion test after 14 days of everolimus treatment as compared to baseline. 
Predefined secondary endpoints were changes in mean systolic and diastolic blood pressure 
during standardized home blood pressure measurement, change in cardiac index, changes in 
serum potassium level and dose of potassium substitution, changes in 24-hour urine 
aldosterone metabolites, and changes in plasma ACTH, renin, cortisol, DHEA-S, testosterone 
and (17)estradiol levels after 14 days of everolimus treatment as compared to baseline. 
Considering the moderate reproducibility of plasma aldosterone in repeated saline 
infusion tests (21) with a difference of the means by 14%, we defined responders as a 
reduction of ≥ 30% from baseline for our post-hoc analysis. 
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Statistical Analysis 
Data were analyzed using Prism v8.0 (GraphPad Software Inc). Discrete variables are 
expressed as counts (percentages) and continuous variables as medians with interquartile 
ranges (IQR). Statistical analyses were performed using Mann-Whitney test (mouse 
experiments) and nonparametric one-way ANOVA (Friedman) with Dunnett’s post hoc test 
(clinical study data). P-value <0.05 was defined as significant.  
RESULTS 
Increased activity of mTORC1 in APA is not caused by overexpression of mTORC1 
components or its regulators 
Previous studies, including ours, reported increased mTORC1 activity in the majority of 
APAs ((13,19,22); Figure 2A, B). To establish whether the observed increased mTORC1 
activity is due to changes in expression of mTORC1 components or proteins involved in 
mTORC1 regulation, we analyzed the results of deep quantitative mass spectrometry analysis 
of 6 pairs of APA and matched control adrenal cortex samples (19). The expression of 
mTORC1 components was not changed in any APA analyzed (Figure 2C). Three APAs 
displayed increased expression of insulin receptor and/or IGF2 receptor (Figure 2D). 
However, these changes did not correlate with mTORC1 activity (Figure 2B). The expression 
of AMPK components was not altered in APAs (Figure 2E). Adenomas expressed higher 
levels of multiple proteins involved in mTORC1 stimulation in response to amino acids 
(Figure 2F). However, the most pronounced changes were observed in APAs not 
characterized by increased mTORC1 activity (Patients 1 and 4). Thus, most likely, increased 
expression of positive mTORC1 regulators is not the underlying cause of increased mTORC1 
activity in aldosterone-producing adenomas. Further studies are required to determine 
whether elevated mTORC1 activity observed in most PAs is due to common changes in 
activities of known signaling pathways upstream of mTORC1. 
Systemic inhibition of mTORC1 decreases plasma aldosterone levels in mice 
mTORC1 inhibition decreases steroid hormone secretion from primary adrenocortical cells 
and adrenocortical cell lines (13,22). To assess whether mTORC1 affects adrenal steroid 
synthesis in vivo, we systemically treated mice with the mTORC1 inhibitor rapamycin and 
assessed their plasma aldosterone and corticosterone levels. Treatment with rapamycin (24 
hours) reduced adrenal mTORC1 activity (Figure 3A) and significantly reduced plasma 
aldosterone levels (P = 0.007, Figure 3B). Plasma corticosterone levels tended to be lower in 
rapamycin-treated animals, but the difference was not statistically significant (Figure 3B). 
Aldosterone is regulated mainly by Angiotensin II (Ang II). However, the levels of plasma 
Ang II did not change upon rapamycin treatment (Figure 3C). Thus, systemic mTORC1 
inhibition with rapamycin reduces circulating aldosterone levels independent of Ang II. 
Whether rapamycin lowers plasma aldosterone levels directly by affecting aldosterone 
synthesis in the adrenal gland or indirectly by affecting the expression of paracrine factors 
regulating aldosterone synthesis and/or aldosterone metabolism requires further studies. 
Systemic mTORC1 inhibition with everolimus decreases plasma aldosterone levels in some 
primary aldosteronism patients 
To assess whether systemic mTORC1 inhibition could decrease aldosterone levels also in PA 
patients, we designed an open-label, proof-of-concept study on treatment of PA with the oral 
mTORC1 inhibitor everolimus. In this study, subjects received everolimus for two weeks and 
their plasma steroid hormone levels, along with other biochemical and clinical parameters, 
were assessed before and after treatment, as well as after a two-week washout period (Figure 
1A). 14 patients with PA were enrolled, of which 12 completed the study (Figure 1B). One 
drop-out was due to a respiratory tract infection, and another was due to acute pancreatitis 
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requiring hospitalization with full recovery without sequelae. The latter was reported as a 
serious adverse event probably related to everolimus. 10 subjects reported mild to moderate 
adverse events which were mainly skin or mucosal changes. Participant adherence was good, 
as reflected by detectable plasma everolimus levels during the treatment. 
Median post-infusion plasma aldosterone levels were comparable at baseline, after the 
two-week everolimus treatment, and after the washout period (Figure 4A). However, post-
hoc individual subject analysis allowed identification of 4 responders defined by a ≥ 30% 
reduction in plasma aldosterone levels after treatment (Figure 4B). Importantly, aldosterone 
levels in the responder cohort returned to the baseline values after the washout period (Figure 
4B), indicating the causative effect of the treatment. The effect of everolimus appears to be 
specific to aldosterone among the measured steroid hormones, as no similar changes were 
observed for cortisol (Figures 4C, D), testosterone (Figures 5A, B), DHEA-S (Figures 5C, D) 
or (17)estradiol (Figures 5E, F). The apparent reduction in plasma cortisol levels after the 
washout period (Figure 4C) was most likely an artifact due to varying stress levels at repeated 
visits and therefore not-treatment related. The observed changes in aldosterone were not 
accompanied by changes in plasma ACTH concentrations (Figures 4E, F) or serum potassium 
levels (Table 2). Thus, everolimus treatment appears to lower plasma aldosterone in a subset 
of PA patients independently of changes in ACTH or potassium concentration. There was no 
apparent correlation between age, gender, the severity of hypertension, the presence of 
hypokalemia or underlying cause of PA and everolimus response. Thus, further studies are 
needed to distinguish between potential responders and non-responders. 
Everolimus treatment influences 24h urine steroid metabolome 
To distinguish whether the treatment-associated decrease in plasma aldosterone in the 
responder cohort resulted from the decreased synthesis or enhanced metabolism, we 
measured the levels of aldosterone and its major metabolite, tetrahydroaldosterone (TH-Aldo) 
in urine collected over 24 hours. Three responders displayed a marked decrease in urine 
aldosterone and TH-Aldo levels upon everolimus treatment (Figures 6A, B), suggesting 
reduced aldosterone synthesis. It was impossible to determine changes in urine aldosterone 
and TH-Aldo levels in the 4th responder due to the loss of the baseline sample.  Similar to 
plasma measurement, no changes in median urine aldosterone and TH-Aldo concentrations 
were observed when patients were analyzed together (Figures 6A, B). Furthermore, no 
consistent changes in urine cortisol, total glucocorticoid metabolites, testosterone, 11β-
hydroxyandrosterone, and progesterone levels were observed (Figures 6C, D, E, F, G). 
Additionally, no changes were observed in the levels of 11-deoxycorticosterone, 18-
hydroxylated cortisol and corticosterone or corticosterone and its tetrahydro-metabolites. 
Taken together, these data suggest that in a subset of PA patients everolimus specifically 
reduces aldosterone synthesis but does not show a consistent effect on other adrenal steroids, 
including those with mineralocorticoid effects. 
Everolimus treatment decreases blood pressure 
To assess whether everolimus treatment could lower blood pressure in PA patients, we asked 
the study participants to take standardized home blood pressure measurements during the 
trial. Systolic and diastolic blood pressure measurements were significantly improved after 
the everolimus treatment and returned to the baseline values after the washout period (Figures 
7A, B). The observed changes in blood pressure were independent of changes in cardiac 
index (Figure 7C). Thus, everolimus treatment lowers blood pressure in hypertensive PA 
patients. Whether these changes are a consequence of reduced aldosterone levels requires 
further studies. 
Everolimus treatment attenuates renin suppression 
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High aldosterone levels characteristic of PA lead to suppression of renin, a protease secreted 
by the renal glomeruli and involved in the regulation of angiotensin and aldosterone. We 
evaluated whether everolimus treatment would reduce renin suppression. Indeed, plasma 
renin concentrations were significantly increased after the everolimus treatment compared to 
baseline (Figure 7D, E) although still remained in the suppressed range. Heart rate (Figure 
7F), urine volume (Table 2) and copeptin, a marker for stress response and antidiuretic 
hormone (ADH) release, remained unchanged (Figure 7G). Thus, the effect of everolimus on 
plasma renin concentration appears not to be due to volume depletion. Whether this effect is 
due to subtle changes in aldosterone levels or the action of everolimus outside adrenal glands 
remains to be determined.  
DISCUSSION 
Plasma aldosterone levels decreased markedly after everolimus treatment and returned close 
to baseline after the washout period in 4 out of 12 subjects. This pattern was mirrored by 
changes in urinary aldosterone and TH-Aldo levels, strongly suggesting a treatment-related 
reduction in aldosterone synthesis in a subset of PA patients.  
There may be several reasons why everolimus did not lower plasma aldosterone levels in 
all subjects. First, mTORC1 is hyperactivated in most, but not all, PA adrenals (13,22). 
Second, everolimus-response might depend on the nature of molecular event leading to PA 
development and APAs differ considerably on a molecular level (23). While transcriptome 
and methylome analyses have revealed upregulation of genes involved in the Wnt signaling 
pathway (Figure 2A) in APAs with somatic mutations in the gene encoding KCNJ5 (23), the 
molecular characteristics of APAs with less frequent somatic mutations are less well 
described.  Third, even though the genetic basis for sporadic bilateral adrenal hyperplasia is 
still poorly understood (24), germline variations in the KCNJ5 gene might also play a role in 
certain patients with bilateral adrenal hyperplasia (25). Scholl et al. have reported that certain 
macrolides can inhibit excessive aldosterone production caused by KCNJ5G151Rand 
KCNJ5L168R mutations (26). Thus, it is plausible that everolimus, which also has a macrolide 
structure, might inhibit aldosterone production only in adrenocortical cells harboring 
particular KCNJ5 mutations or mutations in another ion channel(s). Further studies are 
required to correlate responsiveness to everolimus treatment with molecular characteristics of 
PA adrenal glands. 
Although plasma aldosterone levels were prominently reduced only in 4 study 
participants, we observed a general reduction in median systolic and diastolic blood pressure 
and increased renin levels after the 2-week treatment with everolimus. It is possible that these 
changes were related to subtle changes in aldosterone concentrations that were not detected 
by standardized recumbent saline infusion test or steroid metabolome assessment in 24-hour 
urine. The saline infusion test might not be sensitive enough to evaluate modest changes in 
aldosterone synthesis as the reproducibility of the test has been reported to be moderate (21) 
under renin-angiotensin-aldosterone system (RAAS)-neutral therapy. Furthermore, 
everolimus has been reported to be associated with hypertension (27) rather than 
hypotension. However, it is usually used at higher doses and in combination therapies for 
transplant and cancer patients. Reports on the effect of everolimus alone on blood pressure 
and the RAAS are scarce. Alternatively, everolimus could affect the hypothalamus and 
sympathetic nervous system activity and consecutively lead to increased plasma renin 
concentration (28). It should be noted that a significant proportion of patients took beta 
blockers and central alpha2-agonists which lower renin levels and might have mitigated the 
rise in renin. Nevertheless, this would not explain the parallel fall in blood pressure. In 
addition, as this study was not powered to detect changes in blood pressure, a further study 
comprising a larger cohort and a longer treatment period is needed to elucidate potential 
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effects of everolimus on the RAAS and blood pressure, and to fully understand the 
differences between potential responders and non-responders. Moreover, considering the 
potential side-effects and the finding from a recent retrospective cohort study that only an 
increase in plasma renin activity to ≥1 µg/L/h reverses the excess risk for cardiovascular 
morbidity and mortality in PA as compared to essential hypertension (29), the most 
appropriate dosage or an mTORC1-inhibiting compound with an improved efficacy and 
safety profile should be investigated.  
One limitation of our study is the single-arm open-label design and therefore only 
changes from baseline can be reported. Furthermore, the included subjects had only mild 
hypertension most likely due to diagnosis at earlier stages of the disease resulting from an 
increasing awareness for primary aldosteronism and broadened indications for screening. 
Therefore, the study population might not represent the historically described population with 
primary aldosteronism which presented most often with moderate to severe hypertension 
(30,31). 
In conclusion, we suggest that increased mTORC1 activity in APA is most likely due to 
downstream signaling changes rather than to overexpression of its components or canonical 
positive regulators. We provide evidence that mTORC1 inhibition selectively lowers 
aldosterone in mice and a subset of PA patients, and significantly reduces blood pressure and 
renin suppression in the tested patient cohort. Our findings highlight that the mTORC1 
signaling pathway plays a relevant role in primary aldosteronism. 
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Figure 1.  Clinical study design. (A) Study timeline. (B) Enrollment. 
Figure 2. Increased activity of mTORC1 in APA is not caused by overexpression of 
mTORC1 components or its regulators. (A) Signaling upstream of mTORC1. mTORC1 
consists of mTOR, mLST8, and RAPTOR and responds to a diverse set of inputs, most 
notably growth factors, amino acids, and cellular energy levels. Insulin and insulin-like 
growth factors (IGFs) activate mTORC1 by binding to their cognate receptors, which leads to 
PI3K stimulation and PDK1-dependent Akt activation. Akt phosphorylates and inactivates 
TSC2, a member of the TSC complex that functions as a GTPase-activating protein (GAP) 
toward RHEB. GTP-bound RHEB binds and activates mTORC1 (32). Amino acids stimulate 
mTORC1 by modulating the activity of various proteins and protein complexes that regulate 
RAG heterodimers. Activated RAGs recruit mTORC1 to the lysosomal surface where it 
interacts with RHEB. Amino acids are required for mTORC1 activation in response to any 
other signal (33). Energy stress (manifested as increased AMP/ATP ratio) suppresses 
mTORC1 signaling by activating AMPK, which in turn inhibits RAPTOR and activates the 
TSC complex. Bold font indicates protein complexes (32). (B) mTORC1 activity in 
aldosterone-producing adenomas (APAs). Levels of S6-pSer240/244, a well-established 
marker of mTORC1 signaling, were quantified in APA and control adrenal cortex samples 
(Ctrl) of the same patient by immunoblot. (C-F) Expression of (C) mTORC1 components 
and proteins involved in mTORC1 regulation by (D) growth factors, (E) AMPK, and (F) 
amino acids in APAs. Proteins were quantified in APA and matched control adrenal cortex 
samples by deep quantitative mass spectrometry. Proteins were considered deregulated in 
APA when they were differentially expressed by >1.5 fold (P < 0.05, ANOVA-based t test) 
or they were detected exclusively either in Ctrl or APA samples. 
Figure 3. Systemic inhibition of mTORC1 decreases plasma aldosterone levels in mice. 
(A) Immunoblot evaluating levels of S6K-pThr389, the activated form of S6K, and direct 
target of mTORC1 signaling, in adrenal glands of mice treated with vehicle or rapamycin for 
24 hours. (B) Plasma aldosterone, corticosterone and (C) Angiotensin II levels in mice 
treated with vehicle or rapamycin for 24 hours. Data are shown as medians. N = 4 to 8 
animals per group. ** P < 0.01 (Mann-Whitney test).  
Figure 4. Systemic mTORC1 inhibition with everolimus decreases plasma aldosterone 
levels in some primary aldosteronism patients. (A-D) Plasma hormone levels at the 
baseline (V3, day 0), after a 2-week everolimus treatment (V5, day 15) and a 2-week wash-
out period (V6, day 28). (A) Overall, post-infusion plasma aldosterone levels were not 
significantly changed (P = 0.436) after a 2-week everolimus treatment, (B) but a marked 
reduction was observed in 4 subjects shown as responders in red as opposed to non-
responders in grey. (C, D) This pattern was not observed for cortisol which was significantly 
lower after wash-out (P = 0.017, post hoc adjusted P = 0.024). (E, F) The tendency of 
reduced aldosterone levels and decreased cortisol was not reflected by changes in ACTH (P = 
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0.320). Data are shown with median and interquartile range (IQR). Data were analyzed with 
nonparametric one-way ANOVA (Friedman) and Dunnett’s post hoc test. N = 10 due to 
missing values at V6 for subject 11 and 12 for aldosterone, N = 12 for cortisol and ACTH. *P 
< 0.05.  
Figure 5. Systemic mTORC1 inhibition with everolimus does not influence sex 
hormones. After a 2-week everolimus treatment, no significant changes were observed in 
plasma testosterone (P = 0.078, (A) men, (B) women), DHEA-S (P = 0. 179, (C) men, (D) 
women) or (17)estradiol (P = 0.843, (E) men, (F) women). Data are shown with median and 
IQR. N = 12. Data analysis with Friedman test. Subjects which showed a marked decrease of 
plasma aldosterone after everolimus treatment are marked as responders in red, non-
responders are marked in grey. Men and women are shown separately due to differing 
reference ranges and variability of sex hormones during the menstrual cylce. DHEA-S = 
dehydroepiandrosterone-sulfate. 
Figure 6. Everolimus treatment influences 24h urine steroid metabolome. Steroid 
hormone metabolites were normalized to 24-hour creatinine to account for possible 
incomplete urine collection. The 24-hour excretion of (A) aldosterone (P = 0.629), (B) 
tetrahydroaldosterone (P = 0.732), (C) cortisol (P = 0.100), (D) total glucocorticoid 
metabolites (tetrahydrocortisol, 5α-tetrahydrocortisol, tetrahydrocortisone, α- and β-
cortolone, β-cortol, cortexolone, cortisol and cortisone; P = 0.976), (E) testosterone (P = 
0.470), (F) 11β-hydroxyandrosterone (P = 0.470) and (G) progesterone (P = 0.117) were not 
significantly different after a 2-week everolimus treatment (V5, day 15) and a 2-week wash-
out (V6, day 28) as compared to baseline (V3, day 0). Subjects which showed a marked 
decrease of plasma aldosterone after everolimus treatment are marked as responders in red, 
non-responders are marked in grey. Data are shown with median and IQR. Data analysis with 
nonparametric one-way ANOVA (Friedman) and Dunnett’s post hoc test. N = 11 as baseline 
24-hour urine for steroid metabolome from subject one was not collected. 
Figure 7. Everolimus treatment decreases blood pressure and attenuates renin 
suppression. (A-B) 7-day home blood pressure measurements showed a significant decrease 
in systolic (P = 0.001, adjusted P = 0.011 day 15 vs. day 0 and P >0.999 day 28 vs. day 0) 
and diastolic (P < 0.026, adjusted P = 0.042 day 15 vs. day 0 and P > 0.999 day 28 vs. day 0) 
blood pressure. (C) Cardiac index (P = 0.179) was not significantly changed. (D, E) Renin 
increased significantly after everolimus treatment (P < 0.0001, adjusted P = 0.001 day 15 vs. 
day 0 and P = 0.023 day 28 vs. day 0). (F) heart rate (P = 0.168) and (G) Copeptin (P = 
0.937) showed no significant difference. Subjects which showed a marked decrease of plasma 
aldosterone after everolimus treatment are marked as responders in red, non-responders are 
marked in grey. Data in D are shown with median and IQR. Data analysis with nonparametric 
one-way ANOVA (Friedman) and Dunnett’s post hoc test. N = 10 for blood pressure and 
heart rate, N = 11 for renin due to missing data, N = 12 for cardiac index and copeptin. *P < 
0.05, ***P < 0.001. 
Table 1. Demographic and clinical baseline characteristics of subjects. Discrete variables 
are expressed as counts with percentages (%) and continuous variables as median with 
interquartile range (IQR).  
Characteristic  
Sex  
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- male, n (%) 7 (58%) 
- female, n (%) 5 (42%) 
Ethnicity   
- caucasian, n (%) 9 (75%) 
- african, n (%) 3 (25%) 
Age, years 49 (44-58) 
Body mass index, kg/m2 32.6 (26.3-35.4) 
Duration of hypertension, years 2.5 (0.25-7) 
7-day home blood pressure  
- systolic, mmHg 132 (129-150) 
- diastolic, mmHg 87 (80-94) 
Number of antihypertensive drugs, n 2.5 (1-5) 
Lateralisation on adrenal venous sampling, n (%) 6/10 (60%) 
Histology  
- aldosterone producing adenoma, n (%) 3 (25%) 
- bilateral adrenal hyperplasia, n (%) 4 (33%) 
- micronodular hyperplasia, n (%) 3 (25%) 
- unknown, n (%) 2 (17%) 
Hypokalemia, n (%) 10 (83%) 
Potassium substitution, mmol/day 100 (60-140) 
Plasma aldosterone, pmol/l 640 (504-1054) 
Direct renin concentration, ng/l 0.7 (0.3-1.4) 
Serum potassium, mmol/l 4.1 (3.7-4.3) 
GFR, ml/min/1.73 100 (85-108) 
HbA1c, % 5.5 (5.3-5.8) 
Total cholesterol, mmol/l 4.98 (4.21-5.40) 
LDL, mmol/l 2.62 (2.25-3.08) 
HDL, mmol/l 1.40 (1.16-1.54) 
Triglycerides, mmol/l 1.8 (1.21-2.50) 
CRP, mg/l 2.6 (1.3-4.9) 
Table 2. Everolimus lowers plasma aldosterone levels in some primary aldosteronism 
patients, decreases blood pressure and attenuates renin suppression 
 V 3 (day 0)  V5 (day 15) V6 (day 28) 
Basal plasma aldosterone (pmol/l) 640 (504-1054) 668 (468-831) 675 (427-981) 
Direct renin concentration (ng/l) 0.7 (0.3-1.4) 1.5 (0.7-4.7)*** 0.7 (0.2-3.9)* 
Plasma cortisol (nmol/l) 238 (185-267) 214 (166-298) 167 (139-236)* 
ACTH (pg/ml) 13.5 (8.4-22.3) 12.0 (6.2-21.8) 14.1 (8.4-19.1) 
Copeptin (pmol/l) 6 (3.9-8.9) 6 (4.7-9.2) 5.7 (3.4-9.7) 
Serum potassium (mmol/) 4.1 (3.7-4.3) 4.0 (3.9-4.2) 3.8 (3.7-4.0) 
Potassium substitution (mmol/day) 100 (60-140) 120 (60-140) 120 (60-140) 
7-day home blood pressure     
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- Systolic (mmHg) 132 (129-150) 130 (125-140)* 134 (129-149) 
- Diastolic (mmHg) 87 (80-94) 84 (78-90)* 86 (82-95) 
Cardiac index (l/min/m2) 2.5 (1.6-3.4) 2.7 (2.4-3.3) 2.5 (1.5-2.9) 
Heart rate (beats per minute) 55 (52-68) 61 (54-66) 63 (57-66) 
 Comparison of baseline measurements (V3, day 0), after a 2-week treatment with everolimus (V5, day 15) and 
after a 2-week wash-out period (V6, day 28). Data are shown with median and IQR. * P < 0.05, *** P < 0.001 
versus baseline (Friedman test with Dunnett’s post hoc test).   
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